You are here

WHICH WILL GROW WITH INCREASING AWARENESS AND A BETTER TEST.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 2955
Amount: $48,954.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1985
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
University City Science Ctr.
Philadelphia, PA 19104
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MASAAKI ISHIGAMI
 PRINCIPAL INVESTIGATOR
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

WHICH WILL GROW WITH INCREASING AWARENESS AND A BETTER TEST.THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP A NEW PHARMACOLOGICAL MEANS TO PROTECT THE KIDNEY FROM ISCHEMIA. A COMPOUND WAS REPORTED TO PROTECT THE BRAIN AND THE HEART FROM ISCHEMIA. DATA SUGGEST THAT THE MECHANISM OF PROTECTION MAY BE DIFFERENT FROM THAT OF OTHER DRUGS WHICH ARE KNOWN TO PROTECT AGAINST ISCHEMIA. WE HAVE PRELIMINARY EVIDENCE THAT THUS WE PROPOSE TO SYSTEMATICALLY STUDY THE EFFICACY OF THIS COMPOUND USING A WELL-KNOWN RAT MODEL. THE FIRST GOAL IS TO EVALUATE THE PROTECTIVE EFFECT OF THIS COMPOUND AGAINST EXPERIMENTALLY INDUCED POSTISCHEMIC ACUTE RENAL FAILURE BY DERIVING A DOSE RESPONSE CURVE. THE SECOND GOAL IS TO EXAMINE THE EFFECT OF THIS COMPOUND IN EXPERIMENTS WHEREBY THE COMPOUND IS ADMINISTERED EITHER BEFORE OR AFTER THE ISCHEMIA. IF IT PROTECTS THE KIDNEY AGAINST ISCHEMIA EVEN IN POSTISCHEMIC ADDITION, THEN IT WILL HAVE MORE SIGNIFICANT CLINICAL VALUE. THE THIRD GOAL IS TO EXAMINE WHETHER OR NOT A SYNERGISTIC PROTECTIVE EFFECT COULD BE ACHIEVED BY ADMINISTERING THIS COMPOUND TOGETHER WITH OTHER DRUGS KNOWN TO PROTECT THE KIDNEY AGAINST ISCHEMIA.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government